49 results
Keyword Duoplavin Remove keyword
-
List item
Withdrawn application: DuoPlavin
date of withdrawal: 23/05/2008, Initial authorisation, Last updated: 27/05/2008DuoPlavin: Withdrawn application … MARKETING APPLICATION for DUOPLAVIN International non-proprietary … marketing authorisation for DuoPlavin for the prevention of atherothrombotic … -
List item
Human medicine European public assessment report (EPAR): DuoPlavin
clopidogrel, acetylsalicylic acid, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 14/03/2010, Revision: 28, Authorised, Last updated: 16/02/2023DuoPlavin Cardiovascular Diseases Heart … DuoPlavin … EMA/886716/2022 EMEA/H/C/001143 DuoPlavin (clopidogrel / acetylsalicylic … -
List item
Press release: Sanofi Pharma Bristol-Myers Squibb SNC withdraws its marketing authorisation application for DuoPlavin
Last updated: 27/05/2008authorisation application for DuoPlavin … authorisation application for DuoPlavin … authorisation application for DuoPlavin The European Medicines … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel / Acetylsalicylic acid Mylan
acetylsalicylic acid, clopidogrel hydrogen sulfate, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 09/01/2020,
, Revision: 4, Authorised, Last updated: 02/08/2022
authorised in the EU called DuoPlavin. How is Clopidogrel/Acetylsalicylic … with the reference medicine, DuoPlavin, and do not need to be repeated … and to be bioequivalent to DuoPlavin. Therefore, the Agency’s … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022
CHMP, Last updated: 11/11/2022DuoPlavin … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP): 14-17 December 2009
CHMP, Last updated: 11/02/2010DuoPlavin … Squibb Pharma EEIG, and DuoPlavin (Clopidogrel/acetylsalicylic … The review for DuoCover and DuoPlavin began on 25 March 2009 with … -
List item
Human medicine European public assessment report (EPAR): Iscover
clopidogrel, Stroke; Peripheral Vascular Diseases; Atrial Fibrillation; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 14/07/1998, Revision: 49, Authorised, Last updated: 16/02/2023 -
List item
Human medicine European public assessment report (EPAR): Plavix
clopidogrel hydrogen sulfate, Stroke; Peripheral Vascular Diseases; Atrial Fibrillation; Myocardial Infarction; Acute Coronary Syndrome
Date of authorisation: 15/07/1998, Revision: 48, Authorised, Last updated: 15/02/2023 -
List item
Human medicine European public assessment report (EPAR): Clopidogrel/Acetylsalicylic acid Teva
clopidogrel, acetylsalicylic acid, Acute Coronary Syndrome; Myocardial Infarction
Date of authorisation: 01/09/2014, Revision: 1, Withdrawn, Last updated: 28/04/2017 -
List item
Committee for Medicinal Products for Human Use (CHMP): 7-10 November 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/11/2022 to 10/11/2022, Last updated: 10/01/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 07/03/2022 to 10/03/2022, Last updated: 22/11/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 February 2023
European Medicines Agency, Amsterdam, the Netherlands, from 20/02/2023 to 23/02/2023, Last updated: 20/02/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 08/02/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 4-7 July 2022
European Medicines Agency, Amsterdam, the Netherlands, from 04/07/2022 to 07/07/2022, Last updated: 04/07/2022 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/03/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 20-23 June 2022
European Medicines Agency, Amsterdam, the Netherlands, from 20/06/2022 to 23/06/2022, Last updated: 18/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 11-14 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 11/10/2021 to 14/10/2021, Last updated: 20/01/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 6-9 July 2020
European Medicines Agency, Amsterdam, the Netherlands, from 06/07/2020 to 09/07/2020, Last updated: 10/12/2020 -
List item
Committee for Medicinal Products for Human Use (CHMP): 24-27 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 24/01/2022 to 27/01/2022, Last updated: 16/03/2022 -
List item
Newsletters (updated)
Last updated: 09/03/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 12-15 December 2016
European Medicines Agency, London, UK, from 12/12/2016 to 15/12/2016, Last updated: 06/01/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 September 2018
European Medicines Agency, London, UK, from 17/09/2018 to 20/09/2018, Last updated: 31/10/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 5-8 March 2018
European Medicines Agency, London, UK, from 05/03/2018 to 08/03/2018, Last updated: 05/03/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 15-18 March 2010
European Medicines Agency, London, UK, from 15/03/2010 to 18/03/2010, Last updated: 15/02/2010